Skip to content ↓



Download RSS feed: News Articles / In the Media / Audio

Displaying 16 - 30 of 49 news clips related to this topic.

CBC News

MIT researchers have found that some inactive ingredients in medications could play a role in triggering irritation or allergic reactions, reports Bob McDonald for CBC Radio. The researchers hope that, “pharmaceutical companies provide more information to doctors, and that alternative drug formulas can be developed for people with allergies or sensitivities.”


Prof. Giovanni Traverso speaks with STAT reporter Shraddha Chakradhar about a study examining how the inactive substances in most medications could trigger a patient’s allergies and intolerances. “As you start taking more and more tablets, then you are also taking more and more of some of these ingredients,” says Traverso. “We want to raise awareness that these ingredients are there.”

NBC News

NBC News reporter Linda Caroll writes about a new study by MIT researchers showing that inactive ingredients in medications could lead to adverse reactions in some patients. The researchers found that some of the inactive ingredients “can worsen symptoms in people with conditions such as irritable bowel syndrome, or IBS.”


Gizmodo reporter Ed Cara writes about a study by MIT researchers have finds “inactive” ingredients in pills could trigger a patient’s allergies or intolerances. “We’re not saying that everyone should stop taking these medications,” explains Prof. Giovanni Traverso. “But people with an allergy or intolerance should definitely have the opportunity to find out if they have to worry about certain medications.”


MIT researchers have found that many pills contain “inactive” ingredients that could be troublesome for patients, reports Richard Harris for NPR. Prof. Giovanni Traverso explains that if a patient with lactose intolerance takes a pill containing lactose, “it's probably not going to manifest in any significant symptoms. But as the number of pills you're taking [increases], then certainly you might cross that threshold."

Associated Press

AP reporter Lauran Neergaard writes that a new study by MIT researchers finds that pills often contain “inactive” ingredients capable of causing allergic or gastrointestinal reactions. The researchers found that “it’s hard for those patients, or even their doctors, to tell if a pill contains an extra ingredient they should avoid,” Neergaard explains.


A team of researchers led by Prof. J. Christopher Love has developed a system to produce on-demand clinical-grade vaccines and drugs, writes Dr. Francis Collins on the NIH Director’s Blog. In addition to allowing on site production for hospitals the systems could also “produce biologic treatments specially tailored to attack the cancer of a particular individual,” suggests Collins.


Writing for STAT, Karen Weintraub spotlights Prof. J. Christopher Love’s work developing a new desktop drug manufacturing process that can produce thousands of doses of biopharmaceuticals on demand. “I think in the long run there’ll be an opportunity to think about manufacturing for patients in a new way,” says Love.

The Boston Globe

Alumni Keith Dionne and Frank Gentile, who met as graduate students in 1983, have launched a biotech company based on how cells detoxify and repair themselves, reports Jonathan Saltzman of The Boston Globe. Saltzman explains that by creating drugs to induce a process called autophagy, Dionne and Gentile hope to “help cells rid themselves of debris associated with diseases” like Alzheimer’s and Parkinson’s.

CBS Boston

CBS Boston spotlights how Portal Instruments, an MIT startup, is bringing a needle-free injector to the market, which could change the way people take medicine. The device, “fires a pressurized spray to penetrate the skin, instead of piercing the skin with traditional needles.”

The Economist

The Economist writes about new research from Prof. Chris Voigt, in which “he and his colleagues demonstrate how to control customised cells with coloured light.”

The Wall Street Journal

Wall Street Journal reporter James Hagerty writes about the life and legacy of Henri Termeer, a life member of the MIT Corporation known for his work as a pioneering leader in the field of biotechnology.


Xconomy reporter Ben Fidler writes about the life and legacy of Henri Termeer, a life member of the MIT Corporation who died at age 71. Institute Prof. Phillip Sharp explains that Termeer was, “a transformational leader in biotechnology of orphan diseases. Many children now have hope of a healthy life because of his vision and 40 years of creative business leadership.”

Boston Globe

Henri Termeer, a life member of the MIT Corporation who was known as one of the founding fathers of the biotech industry, died at age 71, write Robert Weisman and Bryan Marquard for The Boston Globe. Termeer was, “a key leader in the biotech revolution that placed Massachusetts at the nexus of cutting-edge research and development.”

New York Times

In an article for The New York Times, Shefali Luthra writes about innovative solutions to combat rising prescription drug prices. Luthra speaks with Jose Gomez-Marquez, an instructor at MIT, about his lab, which promotes do-it-yourself medical technology. “If you have extreme health care circumstances, you will find extreme health care ingenuity,” Gomez-Marquez explains.